BRAFV600E is associated with increased uPA levels in papillary thyroid cancer

E. Ashlie Darr, Theodore S. Nowicki, Melanie E. MacEwan, Julie Dunbar, Codrin Iacob, Jan Geliebter

Research output: Contribution to journalReview article

Abstract

Objectives: Papillary thyroid carcinomas (PTC) with the BRAFV600E mutation have been associated with greater local invasion and regional metastasis. The aim of this study is to determine the extent to which BRAFV600E mutation status predicts upregulation of the urokinase plasminogen activator (uPA), an important mediator of invasion and metastasis, in patient samples of PTC. Study Design: Prospective study using 13 patient thyroid tissue samples obtained over 6 years at the New York Eye & Ear Infirmary. Methods: DNA and RNA were obtained from patient PTC and matched normal thyroid tissue samples using the Trizol method. BRAFV600E genotyping was performed using the TaqMan SNP assay, and RNA was analyzed for differences in uPA transcription levels (relative to matched normal thyroid tissue) by qRT-PCR. Results: 54% of the PTC samples possessed the BRAFV600E mutation. PTC samples with the BRAFV600E mutation displayed significantly higher uPA transcription levels than those samples with wild-type BRAF (5.883 vs. 1.27-fold higher RNA levels than corresponding normal thyroid tissue, p<0.05, Wilcoxon signed-rank test). Additionally, uPA RNA levels were significantly higher in patients with nodal metastasis (p<0.05). Conclusions: These data provide new evidence of the roles of BRAF V600E and uPA in PTC invasive pathology, and demonstrate for the first time that BRAFV600E status is able to predict higher uPA levels in PTC.

Original languageEnglish (US)
JournalLaryngoscope
Volume121
Issue numberSUPPL. 5
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Plasminogen Activators
Urokinase-Type Plasminogen Activator
Thyroid Gland
RNA
Mutation
Neoplasm Metastasis
Nonparametric Statistics
Papillary Thyroid cancer
Single Nucleotide Polymorphism
Ear
Up-Regulation
Prospective Studies
Pathology
Polymerase Chain Reaction
DNA

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Ashlie Darr, E., Nowicki, T. S., MacEwan, M. E., Dunbar, J., Iacob, C., & Geliebter, J. (2011). BRAFV600E is associated with increased uPA levels in papillary thyroid cancer. Laryngoscope, 121(SUPPL. 5). https://doi.org/10.1002/lary.22229

BRAFV600E is associated with increased uPA levels in papillary thyroid cancer. / Ashlie Darr, E.; Nowicki, Theodore S.; MacEwan, Melanie E.; Dunbar, Julie; Iacob, Codrin; Geliebter, Jan.

In: Laryngoscope, Vol. 121, No. SUPPL. 5, 2011.

Research output: Contribution to journalReview article

Ashlie Darr, E, Nowicki, TS, MacEwan, ME, Dunbar, J, Iacob, C & Geliebter, J 2011, 'BRAFV600E is associated with increased uPA levels in papillary thyroid cancer', Laryngoscope, vol. 121, no. SUPPL. 5. https://doi.org/10.1002/lary.22229
Ashlie Darr, E. ; Nowicki, Theodore S. ; MacEwan, Melanie E. ; Dunbar, Julie ; Iacob, Codrin ; Geliebter, Jan. / BRAFV600E is associated with increased uPA levels in papillary thyroid cancer. In: Laryngoscope. 2011 ; Vol. 121, No. SUPPL. 5.
@article{dc2f0d6e7412457f893d4f8d166d33ef,
title = "BRAFV600E is associated with increased uPA levels in papillary thyroid cancer",
abstract = "Objectives: Papillary thyroid carcinomas (PTC) with the BRAFV600E mutation have been associated with greater local invasion and regional metastasis. The aim of this study is to determine the extent to which BRAFV600E mutation status predicts upregulation of the urokinase plasminogen activator (uPA), an important mediator of invasion and metastasis, in patient samples of PTC. Study Design: Prospective study using 13 patient thyroid tissue samples obtained over 6 years at the New York Eye & Ear Infirmary. Methods: DNA and RNA were obtained from patient PTC and matched normal thyroid tissue samples using the Trizol method. BRAFV600E genotyping was performed using the TaqMan SNP assay, and RNA was analyzed for differences in uPA transcription levels (relative to matched normal thyroid tissue) by qRT-PCR. Results: 54{\%} of the PTC samples possessed the BRAFV600E mutation. PTC samples with the BRAFV600E mutation displayed significantly higher uPA transcription levels than those samples with wild-type BRAF (5.883 vs. 1.27-fold higher RNA levels than corresponding normal thyroid tissue, p<0.05, Wilcoxon signed-rank test). Additionally, uPA RNA levels were significantly higher in patients with nodal metastasis (p<0.05). Conclusions: These data provide new evidence of the roles of BRAF V600E and uPA in PTC invasive pathology, and demonstrate for the first time that BRAFV600E status is able to predict higher uPA levels in PTC.",
author = "{Ashlie Darr}, E. and Nowicki, {Theodore S.} and MacEwan, {Melanie E.} and Julie Dunbar and Codrin Iacob and Jan Geliebter",
year = "2011",
doi = "10.1002/lary.22229",
language = "English (US)",
volume = "121",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "SUPPL. 5",

}

TY - JOUR

T1 - BRAFV600E is associated with increased uPA levels in papillary thyroid cancer

AU - Ashlie Darr, E.

AU - Nowicki, Theodore S.

AU - MacEwan, Melanie E.

AU - Dunbar, Julie

AU - Iacob, Codrin

AU - Geliebter, Jan

PY - 2011

Y1 - 2011

N2 - Objectives: Papillary thyroid carcinomas (PTC) with the BRAFV600E mutation have been associated with greater local invasion and regional metastasis. The aim of this study is to determine the extent to which BRAFV600E mutation status predicts upregulation of the urokinase plasminogen activator (uPA), an important mediator of invasion and metastasis, in patient samples of PTC. Study Design: Prospective study using 13 patient thyroid tissue samples obtained over 6 years at the New York Eye & Ear Infirmary. Methods: DNA and RNA were obtained from patient PTC and matched normal thyroid tissue samples using the Trizol method. BRAFV600E genotyping was performed using the TaqMan SNP assay, and RNA was analyzed for differences in uPA transcription levels (relative to matched normal thyroid tissue) by qRT-PCR. Results: 54% of the PTC samples possessed the BRAFV600E mutation. PTC samples with the BRAFV600E mutation displayed significantly higher uPA transcription levels than those samples with wild-type BRAF (5.883 vs. 1.27-fold higher RNA levels than corresponding normal thyroid tissue, p<0.05, Wilcoxon signed-rank test). Additionally, uPA RNA levels were significantly higher in patients with nodal metastasis (p<0.05). Conclusions: These data provide new evidence of the roles of BRAF V600E and uPA in PTC invasive pathology, and demonstrate for the first time that BRAFV600E status is able to predict higher uPA levels in PTC.

AB - Objectives: Papillary thyroid carcinomas (PTC) with the BRAFV600E mutation have been associated with greater local invasion and regional metastasis. The aim of this study is to determine the extent to which BRAFV600E mutation status predicts upregulation of the urokinase plasminogen activator (uPA), an important mediator of invasion and metastasis, in patient samples of PTC. Study Design: Prospective study using 13 patient thyroid tissue samples obtained over 6 years at the New York Eye & Ear Infirmary. Methods: DNA and RNA were obtained from patient PTC and matched normal thyroid tissue samples using the Trizol method. BRAFV600E genotyping was performed using the TaqMan SNP assay, and RNA was analyzed for differences in uPA transcription levels (relative to matched normal thyroid tissue) by qRT-PCR. Results: 54% of the PTC samples possessed the BRAFV600E mutation. PTC samples with the BRAFV600E mutation displayed significantly higher uPA transcription levels than those samples with wild-type BRAF (5.883 vs. 1.27-fold higher RNA levels than corresponding normal thyroid tissue, p<0.05, Wilcoxon signed-rank test). Additionally, uPA RNA levels were significantly higher in patients with nodal metastasis (p<0.05). Conclusions: These data provide new evidence of the roles of BRAF V600E and uPA in PTC invasive pathology, and demonstrate for the first time that BRAFV600E status is able to predict higher uPA levels in PTC.

UR - http://www.scopus.com/inward/record.url?scp=80051981733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051981733&partnerID=8YFLogxK

U2 - 10.1002/lary.22229

DO - 10.1002/lary.22229

M3 - Review article

AN - SCOPUS:80051981733

VL - 121

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - SUPPL. 5

ER -